Publications by authors named "Daniel Canafax"

Claim this Profile
E
Editorial: on the road towards treatment of gastroparesis-accelerating, but do we get closer? Authors' reply.
Braden Kuo, Chris N Barnes, Deanna D Nguyen, David Shaywitz, Maria Grimaldi, Daniel Canafax

Aliment Pharmacol Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study.
Braden Kuo, Chris N Barnes, Deanna D Nguyen, David Shaywitz, Maria Grimaldi, Daniel Canafax

Aliment Pharmacol Ther· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant.
Detlef Albrecht, David Ellis, Daniel M Canafax, Daniel Combs, Pascal Druzgala

Thromb Haemost· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.
Richard P Whitlock, Christopher B Fordyce, Mark G Midei, Dave Ellis, David Garcia, Daniel M Canafax

Thromb Haemost· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrocardiographic and cardiovascular diagnostic characteristics of patients receiving long-term opioid therapy for pain.
Jay W Mason, Ullrich S Schwertschlag, Vicki Klutzaritz, Daniel M Canafax

J Opioid Manag· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of budiodarone in paroxysmal atrial fibrillation.
Michael D Ezekowitz, Rangadham Nagarakanti, Andrzej Lubinski, Olga Bandman, Daniel Canafax

J Interv Card Electrophysiol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin.
Miroslav M Backonja, Daniel M Canafax, Kenneth C Cundy

Pain Med· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.
Linda M Bavisotto, David J Ellis, Peter G Milner, Daniel L Combs, Ian Irwin, Daniel M Canafax

J Clin Pharmacol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials.
Daniel M Canafax, Abhijeet Bhanegaonkar, Murtuza Bharmal, Michael Calloway

BMC Neurol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models.
S Scott Bowersox, Daniel Canafax, Pascal Druzgala, Peter Milner, Jeffrey I Weitz

Thromb Res· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial.
Arthur S Walters, William G Ondo, Clete A Kushida, Philip M Becker, Aaron L Ellenbogen, Daniel M Canafax

Clin Neuropharmacol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.
David J Ellis, Mohammed Haris Usman, Peter G Milner, Daniel M Canafax, Michael D Ezekowitz

Circulation· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.
Clete A Kushida, Arthur S Walters, Philip Becker, Stephen G Thein, A Thomas Perkins, Daniel Canafax

Sleep· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
Kenneth C Cundy, Srikonda Sastry, Wendy Luo, Joan Zou, Tristen L Moors, Daniel M Canafax

J Clin Pharmacol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclosporine monitoring. 1986.
Gilbert J Burckart, Daniel M Canafax, Gary C Yee

Ann Pharmacother· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis